JERUSALEM, April 24, 2026, 18:08 IDT
Shares of Scinai Immunotherapeutics Ltd. surged Friday in U.S. trading, buoyed by news out of Jerusalem: the biotech secured a $2.61 million private placement plus a warrant inducement to help bankroll its contract drug-manufacturing expansion and targeted immunotherapy programs. The company’s American Depositary Shares on Nasdaq soared roughly 82% to $0.8299, after peaking at $1.11 earlier.
The cash raise comes at a delicate time. Scinai is working to reshape its contract development and manufacturing organization, or CDMO — the business that handles drug development and production for clients — hoping it can shore up more reliable revenue, even as it maintains a smaller immunology research unit. According to a filing, the company reported $1.6 million in cash and cash equivalents as of Dec. 31, and its financial statements included a going-concern warning.
Scinai’s annual report flagged a cash shortfall—the company doesn’t have enough on hand to cover a full year of planned operations from the date of its financial statement. CDMO revenue isn’t filling the gap yet, either. That’s the real backdrop for the recent financing grabbing notice, despite its modest size for biotech.
Scinai lined up $0.48 per ADS for 5,208,333 shares, selling to an institutional life-sciences backer, along with a mix of new and returning investors. The deal comes with Series A warrants—good for two years at $0.48—and Series B warrants, exercisable at $0.55 for five years. Those warrants let holders buy more securities at preset prices.
Scinai disclosed it struck a warrant inducement deal with an institutional investor, who’s immediately exercising warrants for 229,310 ADSs at $0.48 each. In exchange, the investor picks up new unregistered warrants covering 458,621 ADSs, set at $0.55 per ADS. The company expects the transactions to wrap up around April 27, pending standard closing conditions.
Scinai is looking to channel the funds—plus its current cash—into beefing up its CDMO platform, pushing customer programs forward, and making targeted bets in its immunotherapy pipeline. A.G.P./Alliance Global Partners was the sole financial adviser on the deal.
This latest financing comes on the heels of the April 6 shakeup that carved out Scinai’s CDMO operations into a newly formed unit, Scinai Biopharma Services Ltd., while the main company slimmed down its R&D setup. Back then, CEO Amir Reichman framed the overhaul as a way to “align our structure with our strategy.” The CDMO is now set up as the core business, with the R&D side running under tighter management. Scinai
Scinai’s CDMO platform now stands on three legs: its biologics and aseptic plant in Jerusalem, the newly acquired Yavne site for small molecules and APIs—bought from Recipharm Israel—and a broader commercial deal with Recipharm’s global network. The company is aiming for roughly $5 million in CDMO revenue by 2026.
The Recipharm deal is central to the pitch. Back in February, Fierce Pharma noted that Recipharm had taken on the role of Scinai’s top choice for late-stage clinical and commercial manufacturing. Scinai, in turn, was picked as Recipharm’s go-to partner for early-stage development. Recipharm CEO Greg Behar called the partnership an “additional, high-quality pathway” for programs coming out of Israel. fiercepharma.com
Scinai posted 2025 revenue of $1.3 million, up from $0.7 million the previous year, but the net loss still landed at $8.3 million. CEO Reichman described the period as one of “focused execution,” citing CDMO gains, reduced R&D spending, and highlighting PC111 as the main value driver. PR Newswire
This isn’t your standard small-cap biotech scramble for trial wins. Instead, Scinai’s aiming to plant its flag in the CDMO sector, where giants like Lonza already dominate the landscape. Lonza, for its part, told Reuters back in January it expects core CDMO sales to climb 11% to 12% in 2026, coming off CHF 6.5 billion in 2025 revenue for that business.
The agreement leaves plenty of risk on the table. Shareholders could see dilution if warrants kick in, and the deal’s not done yet—it still needs to close. Scinai also stays under Nasdaq’s minimum bid price rule unless its ADSs manage to settle at $1 or higher for 10 consecutive sessions before Sept. 8. The company has flagged that if it can’t secure enough funds, it might wind up cutting back, scaling down, or even shutting its doors.
Execution is what matters now, not just a steady stream of announcements. Scinai needs to convert customer programs into real CDMO revenue, all while making sure its early immunology projects—PC111 and the NanoAbs programs picked up from Max Planck-linked and PinCell deals—stay funded. The catch: they’ll need to do it without relying too much on new equity.
